Regeneron/Sanofi to cut price of heart drug in Express Scripts deal

(Reuters) – Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.
https://www.reuters.com/article/us-regeneron-pharms-sanofi-fr-cholestero/regeneron-sanofi-to-cut-price-of-heart-drug-in-express-scripts-deal-idUSKBN1I23FW

Hospitals To Be Required To Post Prices Online As Part Of CMS Push To Increase Transparency

The price lists may still be confusing to consumers, though, because standard rates are like list prices and don’t reflect what insurers and government programs pay. “Given the inherent complexity of hospital billing, making prices easy to understand is clearly a lot easier said than done,” Shawn Gremminger, of Families USA. https://khn.org/morning-breakout/hospitals-to-be-required-to-post-prices-online-as-part-of-cms-push-to-increase-transparency/

Novartis forges forward into digital pharma with FocalView app

There is a growing trend in big pharma to talk up the potential for digital technology to revolutionise operations and Novartis is one of the companies that is most actively announcing steps to explore this possibility.
In August of last year, the company announced a new position, Chief Digital Officer, and the man to take the position, in Bertrand Bodson.
read more http://www.pharmafile.com/news/517158/novartis-forges-forward-digital-pharma-focalview-app

Software That Uses Artificial Intelligence To Screen Eyes For Diabetes Damage Approved By FDA

It’s the first screening device the FDA has authorized that doesn’t need a clinician’s interpretation to look for a particular condition. In other news, the agency also is going to relax its review of next-generation sequencing tests. https://khn.org/morning-breakout/software-that-uses-artificial-intelligence-to-screen-eyes-for-diabetes-damage-approved-by-fda/